Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. - Wikidata - awgldk - TriplyDB

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

http://www.wikidata.org/entity/Q37672900

about

The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation Molecular models of NS3 protease variants of the Hepatitis C virus Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol Maintaining Genome Stability in Defiance of Mitotic DNA Damage Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein Structural basis for Chk1 inhibition by UCN-01 Alternative binding modes of an inhibitor to two different kinases Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket The structure of mitogen-activated protein kinase p38 at 2.1-A resolution Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 Effect of P-glycoprotein on flavopiridol sensitivity Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis Mining gene expression data of multiple sclerosis Pneumocystis carinii contains a functional cell-division-cycle Cdc2 homologue.Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.Structural determinants of PERK inhibitor potency and selectivity Anticancer drug targets: cell cycle and checkpoint control.A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis.Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.Analysis of cyclin D3-cdk4 complexes in fibroblasts expressing and lacking p27(kip1) and p21(cip1).High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin.Multiple cyclin-dependent kinases signals are critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo.Cyclin-dependent kinase inhibitors: novel anticancer agents.The therapeutic potential of flavonoids.Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids Small molecule modulators of cyclin-dependent kinases for cancer therapy.Role of Serine140 in the mode of action of Mycobacterium tuberculosis β-ketoacyl-ACP Reductase (MabA)Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.6,7,4'-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2.Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.Identification of kinase inhibitors that target transcription initiation by RNA polymerase II

P2860

Q24323313-2A66A931-AF15-4801-AA58-84442571CF10 Q24798536-5F9E7B04-FECA-48E5-BBCC-FA1824BEFFD1 Q24805832-8346B496-21C4-45E6-B423-923901F270D2 Q26738970-8D6C68C4-EB5F-4E99-A121-A721127AD5B5 Q26827580-D3CB5550-7E34-4CEC-B60D-E99B1BED77ED Q27625712-7A6F73EA-8FCE-4D3C-9CC7-25413381454A Q27631578-8CA02E20-6B4B-4E8D-BB37-EB524EDBA58D Q27639676-3EA5B8AB-780D-4AFF-8A8D-1D054F033E46 Q27641691-52A2009F-D0C4-45C7-A21D-47884605E0CF Q27734755-9A139E4D-7088-499B-8939-DC5BBA55C4E9 Q27735488-019089AD-B544-49BA-A63C-FDE79B845857 Q27736668-2DC0AD0C-BC24-4F33-BD5C-81C1D1169F95 Q27746054-B0BB5B82-C6E6-4111-B4F6-3D589DC547EB Q28365275-AEF5B1D0-8F76-462C-8538-4B19B3A24225 Q28369193-05345AD0-69A5-45D7-B4B5-A408D75820F7 Q28388041-4F3C4C42-DF46-48D2-B92B-374B08A98C73 Q32104458-4289401C-F979-4CB7-89BF-3FC858A19241 Q33264498-96FA856B-6CF9-4C6F-9057-5D61D1B986A3 Q33716375-03F44987-11E5-4267-9F63-54C09958ECED Q33744382-CA2516B8-1C5E-4A0B-BA90-E8640951D8C1 Q33801116-9AC3EFAB-DFD2-4908-995F-F76639642FE1 Q33890169-FBF137C0-BEC8-4D7C-828A-C61AFD246DE5 Q33910799-E63179AC-570C-4817-9368-9F4D7327BD0E Q33966548-295D2E7C-6B14-414A-A103-D35ADC58E14E Q33981351-E83E1B63-BD11-472B-A776-4172BAA4FBCA Q34047944-EE2D706B-509A-4D56-AEA5-5B4D6D3F2CE0 Q34075028-FEFF8AC0-967F-44F4-B262-4A62C3E4E9AB Q34075072-5FD7AF2D-E484-4B8D-AB99-53C32DC34346 Q34082542-C5FDEDFE-5C3B-432F-911B-C2353BED2C4F Q34090992-4E77B0B8-048B-41E7-BD05-0ECA14613F00 Q34260197-70A9EC67-A86F-497A-BC8C-319E844876B4 Q34293568-D47C98D6-4246-4498-86A3-95E5E4F487FB Q34420138-838DD977-0BE4-4468-B351-A36C174C65E2 Q34581860-9E85EF17-F67D-4D42-B066-AA5CBC92B62A Q34615632-E8E72688-833A-4D83-B811-676940418359 Q34734125-4A0F4BCD-7FF1-4989-A10F-B8F81592F221 Q34811676-60FA9FF4-CA65-4C31-B2AE-90A44690C665 Q35023368-1700EBEA-B002-4646-BC98-E0ACA0B1EA6A Q35445919-1097626B-4E2D-4EDD-B077-10A02B663305 Q35640132-AADD7DEA-3458-4046-9D5C-CF0A62C18FD7

P2860

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

http://www.wikidata.org/entity/Q37672900

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 1996

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Structural basis for specifici ...... man CDK2, a cell cycle kinase.

@en

Structural basis for specifici ...... man CDK2, a cell cycle kinase.

@nl

type

label

Structural basis for specifici ...... man CDK2, a cell cycle kinase.

@en

Structural basis for specifici ...... man CDK2, a cell cycle kinase.

@nl

prefLabel

Structural basis for specifici ...... man CDK2, a cell cycle kinase.

@en

Structural basis for specifici ...... man CDK2, a cell cycle kinase.

@nl

P1433

Q37672900-5998C2E2-3434-40AC-BC38-99B32017FB07

P1476

Q37672900-505A7BAF-8A4F-4189-93F3-6D9C3834F226

P2093

Q37672900-06AD0434-172B-46D6-9BD4-3842BF8D122E

Q37672900-2013E72C-1737-4EAF-9E54-C87C09EE1DEF

Q37672900-4A2EFF95-AA0F-4DD2-9FE3-32CB9A435B2C

Q37672900-9490F910-9E55-4632-8B84-B8E2E6729C90

Q37672900-C0612030-DD6D-43F8-9373-48392B90039F

P2860

Q37672900-04B27508-F2B6-4AA8-B3E7-816DE2399724

Q37672900-09CB5243-0084-42BD-BFAA-C433BCF70D56

Q37672900-2D644D07-9F17-4811-AF96-A734587C05D2

Q37672900-34ABD7F9-2AF7-4E6A-81B3-CF4899575134

Q37672900-3CE0090D-A408-4D31-B579-C0F262B6F224

Q37672900-461D10D7-9D70-4D2B-8526-AD5421935FE3

Q37672900-46BD958D-2926-4E21-954A-283E4FC35F4F

Q37672900-4731501A-A5E1-4167-A9BC-EE0975650A7C

Q37672900-47C424F8-15A7-4117-A324-8CE159180744

Q37672900-558D0461-3C8F-4E62-AFE1-4F630F308F2E

P304

Q37672900-92E5B513-0A71-402E-9D9A-8BFE6242A28F

P31

Q37672900-CBD5F3C4-4B12-4CCE-B12C-69B9797616A3

P356

Q37672900-2A9E07C5-C81E-4809-8122-58D9182C2DED

P407

Q37672900-C8841269-A8FF-4782-B888-24A2D29C316B

P433

Q37672900-A345FDDF-098E-410D-8F5D-006CBFE95C4A

P478

Q37672900-07528AF1-0423-4751-9B15-7550FDC0F6A0

P50

Q37672900-F6786C75-13B4-4BF6-BC89-AC4031CCE990

P577

Q37672900-C5C818E6-CDC5-43A0-A24A-3BB9435720C1

P5875

Q37672900-4C3195DD-B912-4996-B2E9-445CAABCB3E6

P698

Q37672900-04708555-0C79-4346-BF8E-20C8F5B7F30F

P932

Q37672900-69A493A7-060B-4719-B415-97015FA5A703

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Structural basis for specifici ...... uman CDK2, a cell cycle kinase

@en

P2093

E Sausville

http://www.w3.org/2001/XMLSchema#string

H J Mueller-Dieckmann

http://www.w3.org/2001/XMLSchema#string

P J Worland

http://www.w3.org/2001/XMLSchema#string

S H Kim

http://www.w3.org/2001/XMLSchema#string

U Schulze-Gahmen

http://www.w3.org/2001/XMLSchema#string

P2860

Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

Structure of myohemerythrin in the azidomet state at 1.7/1.3 A resolution

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex

Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24)

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

p21 is a universal inhibitor of cyclin kinases

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

P304

2735-2740

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.93.7.2735

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

P577

1996-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14590665

http://www.w3.org/2001/XMLSchema#string

P698

8610110

http://www.w3.org/2001/XMLSchema#string

P932

39700

http://www.w3.org/2001/XMLSchema#string